| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2025 | SHIP OF THESEUS LLC | 1271 QUARRY HALL RD | EAGLEVILLE | PA | 19403-4543 | MONTGOMERY | USA | R44HL158313 | Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant | 000 | 2 | NIH | 12/10/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $2,169,910 ) |
| | 2025 | 2025 | SHIP OF THESEUS LLC | 1271 QUARRY HALL RD | EAGLEVILLE | PA | 19403-4543 | MONTGOMERY | USA | R44HL158313 | Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant | 000 | 2 | NIH | 8/21/2025 | $1,770,171 |
| | 2025 | 2025 | SHIP OF THESEUS LLC | 1271 QUARRY HALL RD | EAGLEVILLE | PA | 19403-4543 | MONTGOMERY | USA | R41CA310331 | Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies | 000 | 1 | NIH | 9/9/2025 | $399,739 |
|
| Issue Date FY: 2024 ( Subtotal = $213,500 ) |
| | 2024 | 2024 | SHIP OF THESEUS LLC | 1271 QUARRY HALL RD | EAGLEVILLE | PA | 19403-4543 | MONTGOMERY | USA | R33HL163739 | Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant | 001 | 3 | NIH | 8/10/2024 | $213,500 |
| | 2024 | 2023 | SHIP OF THESEUS LLC | 1271 QUARRY HALL RD | EAGLEVILLE | PA | 19403-4543 | MONTGOMERY | USA | R33HL163739 | Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant | 000 | 2 | NIH | 3/8/2024 | $0 |
| | 2024 | 2021 | SHIP OF THESEUS LLC | 1271 QUARRY HALL RD | EAGLEVILLE | PA | 19403-4543 | MONTGOMERY | USA | R43HL158313 | Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant | 000 | 1 | NIH | 3/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $230,300 ) |
| | 2023 | 2023 | SHIP OF THESEUS LLC | 1271 QUARRY HALL RD | EAGLEVILLE | PA | 19403-4543 | MONTGOMERY | USA | R33HL163739 | Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant | 000 | 2 | NIH | 9/1/2023 | $230,300 |
|
| Issue Date FY: 2022 ( Subtotal = $457,450 ) |
| | 2022 | 2022 | SHIP OF THESEUS LLC | 5033 WALTON AVE | PHILADELPHIA | PA | 19143-1629 | PHILADELPHIA | USA | R61HL163739 | Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant | 000 | 1 | NIH | 8/17/2022 | $457,450 |
| | 2022 | 2021 | SHIP OF THESEUS LLC | 5033 WALTON AVE | PHILADELPHIA | PA | 19143-1629 | PHILADELPHIA | USA | R43HL158313 | Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant | 000 | 1 | NIH | 10/19/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $293,089 ) |
| | 2021 | 2021 | SHIP OF THESEUS LLC | 5033 WALTON AVE | PHILADELPHIA | PA | 19143-1629 | PHILADELPHIA | USA | R43HL158313 | Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant | 000 | 1 | NIH | 8/6/2021 | $293,089 |
|
|
